Caroline Grandis
Primary Care · Winston Salem, NCNPI 1952634396
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 192 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 38 manufacturers, the largest accounting for just 15.8% — the pattern of someone who eats at a lot of different presentations.
Across 192 payments — averaging $18.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$548
- Dexcom, Inc.$370
- Pfizer$341
- Amgen$266
- AbbVie$224
- Johnson & Johnson$168
- plus $2K from 32 others
What the payments were for
- Food & beverage$3,470100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 35 | $548 |
| Dexcom, Inc. | 10 | $370 |
| Pfizer | 20 | $341 |
| Amgen | 16 | $266 |
| AbbVie | 13 | $224 |
| Johnson & Johnson | 12 | $168 |
| GSK | 9 | $143 |
| Hologic Sales And Service, LLC | 4 | $130 |
| Novartis | 6 | $118 |
| Lilly USA, LLC | 7 | $111 |
| Astellas Pharma US Inc | 7 | $104 |
| Daiichi Sankyo Inc. | 4 | $82 |
| AstraZeneca | 5 | $82 |
| Sanofi-aventis U.S. LLC | 4 | $78 |
| Boehringer Ingelheim | 4 | $72 |
| Merck | 5 | $72 |
| Biohaven Pharmaceuticals, Inc. | 4 | $72 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $71 |
| Abbott | 2 | $49 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $35 |
| Bayer | 2 | $32 |
| Vanda Pharmaceuticals Inc. | 1 | $25 |
| Tactile Systems Technology Inc | 1 | $24 |
| Irhythm Technologies, Inc. | 1 | $24 |
| Abiomed | 1 | $22 |
| Corium, LLC | 1 | $22 |
| Medtronic | 1 | $19 |
| Viatris Specialty LLC | 1 | $19 |
| Phathom Pharmaceuticals, Inc. | 1 | $18 |
| Linus Health, Inc. | 1 | $18 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $16 |
| Sanofi Pasteur Inc. | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $15 |
| Xeris Pharmaceuticals, Inc. | 1 | $14 |
| Mylan Specialty L.p. | 1 | $14 |
| Eisai Inc. | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Genentech USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,470 in reported general payments places this provider in the 85th percentile of 236 primary care providers in North Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 24 | $37,393 |
| FarxigaDapagliflozin Propanediol | 18 | $25,928 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $14,398 |
| Sumatriptan Succinate | 39 | $5,671 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 105 | $3,118 |
| SymbicortBudesonide/Formoterol Fumarate | 14 | $3,087 |
| Rosuvastatin Calcium | 93 | $1,036 |
| Buspirone Hcl | 11 | $487 |
| Duloxetine Hcl | 24 | $470 |
| Tamsulosin Hcl | 16 | $435 |
| Valsartan | 11 | $427 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 19 | $425 |
| Bupropion XlBupropion Hcl | 19 | $407 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 14 | $402 |
| Atorvastatin Calcium | 94 | $397 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $548 | $37,39324 claims |
| AstraZenecaFarxiga, Symbicort | $82 | $29,01532 claims |
| GSKTrelegy Ellipta | $143 | $14,39811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 236 primary care providers in North Carolina.
Other primary care in Winston Salem
- Jennifer RogersWinston Salem$17K
- Jessica AllynRaleigh$21K
- Elizabeth WaltersChapel Hill$14K
- Ragan JohnsonChapel Hill$13K
- Kirkland DickeyPine Hall$11K
- Kimberly WeaverHickory$9K
- Amanda StoneWilmington$9K
- Elizabeth WalshGreensboro$7K
- Mark HollingsworthWilmington$7K
- Crystal GoinsFayetteville$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.